HONG KONG, Aug. 27, 2026 /PRNewswire/ — As a premier global landmark in biotech, BIOHK2026 convenes international biotech hubs, cross-disciplinary industry forums, and high-impact networking events to accelerate cross-border partnerships in Hong Kong.
The official countdown is underway. With just two weeks until BIOHK2026 convenes at the Hong Kong Convention and Exhibition Centre (HKCEC) from September 9-12, 2026, BIOHK2026—organized by the Hong Kong Biotechnology Organization (HKBIO)—serves as a world-class international landmark event bridging biotech innovation, industrial capacity, venture capital, and regulatory bodies. Leveraging Hong Kong’s strategic position as Asia’s premier “Super-Connector” and biotech financing gateway, this 5th annual convention will welcome over 10,000 professional attendees, 400+ world-class speakers, and delegations spanning over 40 countries and regions.
To assist international delegates in maximizing their strategic footprint, HKBIO has published a comprehensive operational guide detailing the core pillars of this year’s convention.
1. Featured Exhibition Pavilions: Landmark Regional & International Innovation Clusters
Spanning expansive exhibition halls hosting nearly 200 global exhibitors, BIOHK2026 brings together prominent regional biotech hubs, state-backed industrial platforms.
Greater Bay Area & Mainland Innovation Hubs: Major regional delegations including Guangzhou and Shenzhen will showcase their dense biotech clusters, pioneering biotech enterprises, clinical trial capacity, and advanced biomanufacturing strength. A central spotlight will also be cast on the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, highlighting cross-border policy synergy, joint research initiatives, and frictionless data and sample flows between Hong Kong and Mainland China.
Leading Institutional & Corporate Delegations: Backed by Mainland China and connected to global markets, Hong Kong serves as an ideal pivot for biotech innovation. As a premier institutional partner, CITIC Group has joined hands with HKBIO for BIOHK2026. As a flagship implementation of CITIC’s strategy, this landmark partnership leverages abundant industrial resources, expert think tanks, and deep market entry experience to fully elevate the scale and international stature of the convention.
Nordic Future Health Pavilion: Co-organized by the Hong Kong Chamber of Commerce in Sweden (HKCCSE) and supported by the Consulate General of Sweden in Hong Kong and AstraZeneca Hong Kong, this dedicated pavilion brings around 10 leading Nordic life science enterprises and organizations directly to the main convention floor. Key participants will showcase breakthrough technologies spanning precision T-cell receptor-engineered T-cell therapies (Anocca), stromal cell therapies (NextCell Pharma), cancer immunotherapies and vaccines (ExpreS2ion Biotechnologies), digital health (Keeada Health, SoftMed), ophthalmology (Uveo), and biotech development (Veltio Pharma).
2. High-Impact Conference Program: 50+ Multi-Track Industry Forums
Across seven dynamic stages hosting over 400 world-class speakers, the four-day conference features high-level keynotes and more than 50 vertical forums bridging global biotech ecosystems:
Frontier Therapeutics & Advanced Sciences: Dedicated tracks covering AI-driven Drug Discovery & Healthcare, Cell and Gene Therapy (CGT) source innovation, Brain-Computer Interface (BCI), Synthetic Biology, Spatiotemporal Omics in infectious diseases, mRNA/Exosome therapies, Longevity & Anti-Aging science, and Modernization of Traditional Chinese Medicine (TCM) and other cutting-edge disciplines.
Global Regulatory, Clinical & Policy Frameworks: High-level keynotes and dedicated sessions exploring regulatory harmonization, highlighting the newly established Hong Kong Centre for Medical Products Regulation (CMPR), GBA Clinical Trial Collaboration via “One Institute, One Center”, and cross-border medical integration. Anchored by these initiatives, BIOHK2026 brings together top regional drug regulators—including representatives from Hong Kong, Singapore, Malaysia, Indonesia and Pakistan—to facilitate international collaboration and empower the global expansion of innovative therapeutics.
Global Cooperation Forum Series: Flagship international sessions exploring cross-border technology transfer, investment, and market access synergies across key global regions—including dedicated tracks for North America & Europe, Latin America, Southeast Asia/ASEAN, Belt and Road Economies, GBA, and specialized regional showcases like Hainan.
Biotech Investment & BD Summits: Capitalizing on Hong Kong’s position as the world’s second-largest biotech financing center—supported by HKEX Chapter 18A enabling non-revenue biotech listings and a robust capital ecosystem—forums will bring together corporate BD leads, investors, and dealmakers to analyze macro trends, primary vs. secondary market valuation, cross-border licensing, and value creation.
3. Concurrent Highlights: Strategic Matchmaking, Pitching & Executive Networking
Complementing the exhibition and conference tracks, BIOHK2026 features high-impact concurrent activities designed to convert participation into actionable dealmaking:
Integrated One2One Partnering Engine (Included with Delegate Pass): Every registered pass holder gains full access to the digital platform. Delegates can utilize multi-dimensional filters—categorizing counterparts by technology modalities, therapeutic focus, development stages, and specific collaboration goals—to pre-book 30-minute face-to-face sessions in dedicated private partnering suites at HKCEC.
BIOHK2026 Pitching Competition: Serving as a premier global launchpad for healthcare innovation, this competitive roadshow stage features high-potential biotech startups, university spin-offs, and early-stage innovators pitching platform technologies directly to rooms filled with global biotech investors, corporate BD leads, and industry mentors.
Regulatory Roundtables & Heavyweight Leaders: Strategic dialogues and closed-door consultations linking biotech developers with industry visionaries and global opinion leaders. Featuring keynotes and insights from renowned heavyweights across policy, academia, and top-tier venture capital, these sessions provide a premier platform to navigate international market access and global growth strategies.
Victoria Harbour Night Cruise Networking: A signature evening event bringing together industry leaders, investors, and international delegates for an exclusive night cruise along Victoria Harbour, providing an inspiring setting to deepen connections and discuss strategic partnerships against Hong Kong’s skyline.
Public Engagement Day: The convention wraps up on Saturday, September 12, with a dedicated Public Engagement Day open to the community, highlighted by two featured tracks: “Junior Scientist: Biotech STEAM Discovery Day” to inspire next-generation scientific curiosity, and “Healthy Futures—Where East Meets West” exploring integrative health, wellness innovation, and science communication.
“BIOHK2026 is engineered as Asia’s premier platform connecting source innovation to global commercialization,” stated an HKBIO spokesperson. “We invite global biotech leaders, investors, and pioneers to gather in Hong Kong this September to capitalize on new market opportunities and shape the future of global healthcare.”
Maximize Your Presence—Pre-Book Your Calendar Today!
September 9-12, 2026 | BIOHK2026—Where Leaders Unite Biotech Advances
We cordially invite global biopharma executives, researchers, investors, regulators, clinical experts, and industry leaders to gather in Hong Kong and explore the new frontiers of biotechnology.
- Registration: https://www.bio-hk.com/
- Exhibition Inquiries: kelvin.chan@hkbio.org.hk
- Media Contact: lily.wong@hkbio.org.hk
For further details, please contact us via the channels above.
About HKBIO
The Hong Kong Biotechnology Organization (HKBIO) is a leading non-profit organization dedicated to advancing the growth, internationalization, and innovation of Hong Kong’s life sciences ecosystem. Bringing together leaders from government, industry, academia, research, and capital markets, HKBIO serves as a Super-Connector, fostering cross-border collaboration, accelerating clinical translation, and supporting the commercialization of biotechnology innovation across the Asia-Pacific region. Through its initiatives, HKBIO continues to strengthen Hong Kong’s position as a leading international biotechnology and healthcare innovation hub while helping transform scientific breakthroughs into real-world healthcare solutions.
For more information, please visit https://www.bio-hk.com/.
